Tocagen Adds Venture Capitalist To Board

San Diego-based cancer therapeutics developer Tocagen said this morning that it has added David R. Parkinson, M.D., a venture partner at New Enterprise Associates, to its board of directors. Parkinson has also previously been at Amgen and Novargtis, and was chief of the Investigational Drug Branch at the National Cancer Institute. Parkinson also is on the boards of Threshold Pharmaceuticals and Cerulean Pharma Inc. and had previously been on the boards of Facet Biotech and Ambit Biosciences Corporation, before both of those companies were acquired. Tocagen is initially focusing on treating an aggressive type of brain cancer, recurrent High Grade Glioma (HGG).